#140, 14315 - 118 AVENUE, EDMONTON, A0
Settles Patent Litigation with Teva
Reports Financial Results for the Three and Six Months Ended June 30, 2026 and Provides Update on Recent Business Progress
Shareholder Meeting Results - Directors Elected at Aurinia Pharmaceuticals
Merger Completed: Aurinia Pharmaceuticals Inc. Merges with Merger Sub
Reports Financial Results for the Three Months Ended March 31, 2026 and Provides Update on Recent Business Progress
To Acquire for $6.955 in Cash per Share Plus a Contingent Value Right
Announces Management Transition
Reports Financial Results for the Three and Twelve Months Ended December 31, 2025 and Provides Update on Recent Business Progress
Q2
Q1
FY 2025
Q3
FY 2023
Tender Offer Statement by Third Party
Registration Statement for Securities to be Offered to Employees
S-3ASR
Effectiveness Notice
Definitive Proxy Statement
Additional Proxy Materials
Amended Schedule 13D - Ownership Report
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities
Amended Tender Offer Statement by Third Party
Supplemental Filing
Amended Registration Statement for Securities of Certain Canadian Issuers